185 related articles for article (PubMed ID: 32507854)
1. Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study.
Pernot S; Pellerin O; Artru P; Montérymard C; Smith D; Raoul JL; De La Fouchardière C; Dahan L; Guimbaud R; Sefrioui D; Jouve JL; Lepage C; Tougeron D; Taieb J;
Br J Cancer; 2020 Aug; 123(4):518-524. PubMed ID: 32507854
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
[TBL] [Abstract][Full Text] [Related]
3. Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.
Pernot S; Artru P; Mithieux F; Marsot J; Watkin E; Pellerin O; Lledo G; Chalabreysse P; Desramé J; Taieb J
Clin Res Hepatol Gastroenterol; 2015 Dec; 39(6):e73-7. PubMed ID: 26141343
[TBL] [Abstract][Full Text] [Related]
4. Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization.
Scevola G; Loreni G; Rastelli M; Sposato S; Ramponi S; Miele V
Med Oncol; 2017 Mar; 34(3):37. PubMed ID: 28160267
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases.
Bhutiani N; Akinwande O; Martin RC
World J Surg; 2016 May; 40(5):1178-90. PubMed ID: 26711640
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases.
Sljivic M; Sever M; Ocvirk J; Mesti T; Brecelj E; Popovic P
Radiol Oncol; 2024 Jun; 58(2):214-220. PubMed ID: 38553252
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.
Martin RC; Scoggins CR; Tomalty D; Schreeder M; Metzger T; Tatum C; Sharma V
J Gastrointest Surg; 2012 Aug; 16(8):1531-8. PubMed ID: 22528576
[TBL] [Abstract][Full Text] [Related]
8. Does Bead Size Affect Patient Outcome in Irinotecan-Loaded Beads Chemoembolization Plus Systemic Chemotherapy Regimens for Liver-Dominant Colorectal Cancer? Results of an Observational Study.
Boeken T; Moussa N; Pernot S; Abed A; Dean C; Taieb J; Sapoval M; Pellerin O
Cardiovasc Intervent Radiol; 2020 Jun; 43(6):866-874. PubMed ID: 32103303
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.
Richardson AJ; Laurence JM; Lam VW
J Vasc Interv Radiol; 2013 Aug; 24(8):1209-17. PubMed ID: 23885916
[TBL] [Abstract][Full Text] [Related]
10. Transarterial Chemoembolisation of Colorectal Liver Metastases with Irinotecan-Loaded Beads: A Bi-institutional Analysis of 125 Treatments in 53 Patients.
Ngo A; von Stempel C; Corbo B; Bandula S; Shiu KK; Raja J; Hague J; Evans J; Kibrya N
Cardiovasc Intervent Radiol; 2019 Jul; 42(7):979-990. PubMed ID: 31044294
[TBL] [Abstract][Full Text] [Related]
11. Fluorouracil, leucovorin and irinotecan combined with intra-arterial hepatic infusion of drug-eluting beads preloaded with irinotecan in unresectable colorectal liver metastases: side effects and results of a concomitant treatment schedule. Clinical investigation.
Kekez D; Badzek S; Prejac J; Gorsic I; Golem H; Librenjak N; Perkov D; Smiljanic R; Plestina S
Tumori; 2014; 100(5):499-503. PubMed ID: 25343542
[TBL] [Abstract][Full Text] [Related]
12. PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer.
Jones RP; Malik HZ; Fenwick SW; Terlizzo M; O'Grady E; Stremitzer S; Gruenberger T; Rees M; Plant G; Figueras J; Albiol M; Adam R; Awad S; Poston GJ
Eur J Surg Oncol; 2016 Dec; 42(12):1866-1872. PubMed ID: 27561844
[TBL] [Abstract][Full Text] [Related]
13. Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial.
Liu Y; Chang W; Zhou B; Wei Y; Tang W; Liang F; Chen Y; Yan Z; Lv M; Ren L; Xu J
Br J Surg; 2021 Apr; 108(4):373-379. PubMed ID: 33611431
[TBL] [Abstract][Full Text] [Related]
14. Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded).
de Baere T; Tselikas L; Boige V; Ducreux M; Malka D; Goéré D; Benahim E; Deschamps F
Bull Cancer; 2017 May; 104(5):402-406. PubMed ID: 27993355
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.
Takahashi T; Shibata Y; Tojima Y; Tsuboi K; Sakamoto E; Kunieda K; Matsuoka H; Suzumura K; Sato M; Naganuma T; Sakamoto J; Morita S; Kondo K
Int J Clin Oncol; 2013 Apr; 18(2):335-42. PubMed ID: 22383023
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of TACE With Irinotecan-loaded Drug-eluting Beads (DEBIRI) in Patients With Liver Metastases from Unresectable Colorectal Cancer.
Ishikawa T; Imai M; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
Anticancer Res; 2023 Aug; 43(8):3647-3651. PubMed ID: 37500124
[TBL] [Abstract][Full Text] [Related]
17. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.
Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C
Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
Tang W; Ren L; Liu T; Ye Q; Wei Y; He G; Lin Q; Wang X; Wang M; Liang F; Cui Y; Xu J
J Clin Oncol; 2020 Sep; 38(27):3175-3184. PubMed ID: 32749938
[TBL] [Abstract][Full Text] [Related]
19. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study.
Fiorentini G; Aliberti C; Tilli M; Mulazzani L; Graziano F; Giordani P; Mambrini A; Montagnani F; Alessandroni P; Catalano V; Coschiera P
Anticancer Res; 2012 Apr; 32(4):1387-95. PubMed ID: 22493375
[TBL] [Abstract][Full Text] [Related]
20. Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI(®)) for colorectal liver metastases does not predict tumour destruction or long-term outcome.
Jones RP; Stättner S; Dunne DF; O'Grady E; Smethurst A; Terlizzo M; Malik HZ; Fenwick SW; Poston GJ
Eur J Surg Oncol; 2013 Oct; 39(10):1122-8. PubMed ID: 23928482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
